Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …

▪ Abstract Normal cellular functioning requires processing of proteins regulating cell cycle,
growth, and apoptosis. The ubiquitin-proteasome pathway (UBP) modulates intracellular …

The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular
proteins, including cell cycle regulatory proteins. Because these pathways are critical for the …

Targeting intracellular protein turnover by inhibiting the ubiquitin–proteasome pathway as a
strategy for cancer therapy is a new addition to our chemotherapeutic armamentarium, and …

Therapeutic strategies for multiple myeloma have dramatically changed in the last two
decades, especially after the introduction of proteasome inhibitors. The first-in-class …

Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment
over the past decade. Many PIs are being developed and evaluated in the preclinical and …

Abstract Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter
clinical trials in cancer patients. Based on results of preclinical studies showing that this …

The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins
and thereby regulates protein levels within the cell. Given this important role in maintaining …

The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its
function is crucial to cellular homeostasis. First synthesized as probes of proteolytic …

Background: The ubiquitin-proteasome system has become a promising novel molecular
target in cancer due to its critical role in cellular protein degradation, its interaction with cell …